Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Endocrinology

Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers

Ziyang Yu, Suqin He, Dannie Wang, Jeffrey Brown, Jamal Saeh and Gary Hattersley
Ziyang Yu
Radius Health, Inc., Waltham, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suqin He
Radius Health, Inc., Waltham, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dannie Wang
Radius Health, Inc., Waltham, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Brown
Radius Health, Inc., Waltham, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamal Saeh
Radius Health, Inc., Waltham, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Hattersley
Radius Health, Inc., Waltham, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2017-3609 Published July 2017
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Abstract

Recent studies have shown that the androgen receptor (AR) is widely expressed across all subtypes of breast cancer, with AR detected in 75-95% of estrogen receptor (ER) positive tumors. Prior to the development of ER-targeted therapy, androgens were used to treat breast cancers with favorable clinical responses. The lack of tissue-selectivity and understanding of mechanism of action of classic androgens led to its declined use in this disease. Selective androgen receptor modulators (SARMs) are a class of molecules developed as tissue selective non-steroidal androgens that modulate AR signaling. However, the effect of SARMs on AR signaling in breast cancer cells is not well understood. RAD140 is an orally available SARM with potent anabolic activity in muscle and bone but a highly attenuated effect in seminal vesicles and prostate. Its efficacy is being evaluated in in vivo xenograft models of AR/ER+ breast cancer. To further our understanding of the mechanism of action of RAD140 in breast cancer cells, we examined the effects of RAD140 on AR and ER signaling pathways. The specificity and selectivity of RAD140 were examined using competitive binding assays for AR, ER, glucocorticoid receptor (GR) and progesterone receptor (PR), and using an AR reporter assay in AR/ER+ ZR-75 breast cancer cells and LNCaP prostate cancer cells. RAD140 was found to bind AR with high affinity and specificity, with 250-fold target selectivity over the next nuclear receptor PR. The AR reporter assay results demonstrated a potent AR agonist activity of RAD140 in ZR-75 breast cancer cells but not in LNCaP prostate cancer cells, in contrast to the full agonist activity of DHT seen in both cell types. RAD140 treatment led to substantial tumor growth inhibition in AR/ER+ breast cancer xenografts. Samples of RAD140-treated xenografts were analyzed by immunocytochemistry, western blotting and quantitative real-time PCR to evaluate the modulation of AR and ER pathways. It was found that the expression of known AR target genes including KLK2, FKBP5 and the tumor suppressor gene, ZBTB16, were potently induced in RAD140-treated tumors. Furthermore, RAD140 led to substantial suppression of known ER target genes including progesterone receptor (PR), TFF1 and GREB1. In conclusion, RAD140 is a potent tissue-selective AR agonist in AR/ER+ breast cancer cells with robust activation of AR targets genes, and a unique mechanism of action that leads to the suppression of ER signaling, and marked anti-tumor activity.

Citation Format: Ziyang Yu, Suqin He, Dannie Wang, Jeffrey Brown, Jamal Saeh, Gary Hattersley. RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3609. doi:10.1158/1538-7445.AM2017-3609

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 77 (13 Supplement)
July 2017
Volume 77, Issue 13 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers
Ziyang Yu, Suqin He, Dannie Wang, Jeffrey Brown, Jamal Saeh and Gary Hattersley
Cancer Res July 1 2017 (77) (13 Supplement) 3609; DOI: 10.1158/1538-7445.AM2017-3609

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers
Ziyang Yu, Suqin He, Dannie Wang, Jeffrey Brown, Jamal Saeh and Gary Hattersley
Cancer Res July 1 2017 (77) (13 Supplement) 3609; DOI: 10.1158/1538-7445.AM2017-3609
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Endocrinology

  • Abstract LB-131: Profile of glucose metabolism in bladder cancer patients and the inhibitory effect of sulforaphane on bladder cancer glycolysis by regulating microRNA expression
  • Abstract 6458: Adverse recurrence prognostic implications of tumor CD47 expression in resected non-small cell lung cancer
  • Abstract 6470: Possibility of digital cytology of intraoperative ascites and lavage fluid in patients with colorectal cancer
Show more Endocrinology

Poster Presentations - Proffered Abstracts

  • Abstract 2084: PocketOnco: A CoreML based app for diagnosis and prognosis of colorectal, breast and skin cancer using multilayered convolutional neural network algorithms
  • Abstract PO-048: MicroRNA-10b is a regulator of cellular viability and proliferation in fibrolamellar carcinoma
  • Abstract PO-055: Pan-cancer metabolic profiling of the tumor microenvironment
Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Nuclear Receptors and Endocrine Oncology Therapies

  • Abstract 3627: Validation of PPARG and RXRA as drivers of bladder cancer
  • Abstract 3611: Proteasome subunit PSMD1 participates in p53 degradation and regulates proliferation of breast cancer cells
  • Abstract 3621: Characterization of the effects of estrogen receptor alpha Y537S and D538G mutations on receptor pharmacology
Show more Poster Presentations - Nuclear Receptors and Endocrine Oncology Therapies
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement